Regulatory Intelligence

Regulatory intelligence helps organizations stay compliant and ahead of evolving drug safety requirements.

Role of Regulatory Intelligence

Regulatory Intelligence relates to the gathering, analyzing, and application of knowledge about regulatory updates to the ever-evolving requirements and guidelines relating to drug safety. Maintaining up- to- date knowledge of Regulatory Intelligence ensures that CROs and Pharmaceutical companies remain compliant with current reporting responsibilities, as well as surveillance requirements and risk management.

Regulatory Intelligence has many practical applications, including:

  • Regulatory Compliance
  • Drug Safety Monitoring
  • Market expansion
  • Crisis and/or Risk Management
  • Regulatory Audits and Inspections
  • Facilitating Market Access
Business worker holding espresso cup and stack of papers looking forward
Several business professionals having fun at a business meeting

Regulatory Intelligence at ProPharma

Regulatory Intelligence is a key pillar at ProPharma, and aims to simplify compliance, reduce risks, and ensure both ProPharma and our clients stay ahead of any regulatory changes. We achieve this by utilising various Regulatory Intelligence tools, Artificial Intelligence, completing monthly manual reviews of authority websites, as well as having a vast network of local knowledge to collect and evaluate local and global regulations.

The thorough analysis of any findings from each of these sources allows for an up-to-date Regulatory Intelligence Repository that colleagues can access to easily answer queries either internally or from clients. Where the answer isn’t already available, ProPharma has the ability to provide fast turnaround responses to ad-hoc requests for Regulatory Intelligence, going as far as offering one- to- one Regulatory Intelligence consultations.

Having access to the most up-to-date global regulation requirements, and the knowledge to interpret these regulations accurately, makes ProPharma completely qualified to perform submissions all over the world. This applies to periodic and expedited submissions, as well as Post-Marketing and Clinical Aggregate Report submissions, and EU product registration and updates in XEVMPD.

Our top priority at ProPharma is regulatory compliance, ensuring that all submissions are performed in accordance with applicable regulations. Due to our Regulatory Intelligence repository and expert interpretations of requirements, ProPharma is proud to consistently post a greater than 99% compliance rate for regulatory submissions, successfully submitting over 2,000 ICSRs per month to health authorities and ethics committees, and distributing reports on-time to investigators and business partners on behalf of our clients.

For clients utilizing our PV submission services, we offer access to the relevant RI for no additional cost, and for clients not utilizing our submissions services, we offer subscriptions to our PV RI information and updates. This information is provided in three different options that build upon each other, allowing the use of a single format or combination of formats. When you have needs, we have answers. Let us know how we can support you today.

Business professionals discussing data around a conference table

Regulatory Intelligence  Services

Stay ahead of regulatory changes with ProPharma's expert regulatory intelligence services. Contact us today to learn how we can support your compliance needs.

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow